|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT2显示文摘 | Herbst RS Giaccone G Schiller JH | 2004 | J Clin Oncol2004，22，5： | 1 |
| 2 | Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase Ⅲ trial-INTACT1 显示文摘 | Giaccone G Herbst RS Manegold C | 2004 | J Clin Oncol2004，22，5： | 1 |
| 3 | Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small-cell lung cancer:a randomized trial显示文摘 | Kris MG Natale RB Herbst RS | 2003 | JAMA2003，290，16： | 1 |
| 4 | Lung Cancer显示文摘 | Herbst RS Heymach JV | 2008 | N Engl J Med2008，359，13： | 1 |
| 5 | Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosin Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors显示文摘 | LoRusso PM Herbst RS Rischin D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 6 | Role of novel targeted therapies in the clinic显示文摘 | Herbst RS | 2005 | Br J Cancer2005，92，1： | 1 |
| 7 | Geftinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT2 显示文摘 | Herbst RS Giaccone G Schiller JH | 2004 | J Clin Oncol2004，22，5： | 1 |
| 8 | Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT2显示文摘 | Herbst RS Giacone G Schiller JH | 2004 | J Clin 0ncol2004，22，5： | 1 |
| 9 | Selective oral epidermal grow factor tyrosine kinase inhbitor ZD1839 is generally well-tolerated and has activity in non- small-cell lung cancer and other solid tumors: results of a phase Ⅰ trial显示文摘 | Herbst RS Maddox AM Rochenberg ML | 2002 | J Clin Oncol2002，20，18： | 1 |
| 10 | Targeting the epidermal gtowth factor receptor in non-small cell lung cancer显示文摘 | Herbst RS Bunn PA Jr | 2003 | Clin Cancer Res2003，9，： | 1 |
| 11 | Lung Cancer in patients under age 40显示文摘 | Skarin AT Herbst RS Leong TL | 2001 | Lung Cancer2001，32，3： | 1 |
| 12 | Efficacy of gefitinib,an inhibitor of epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:a randomized trail显示文摘 | Kris MC Natle RB Herbst RS | 2003 | JAMA2003，290，16： | 1 |
| 13 | Vandetanib plus do-cetaxel versus docetaxel as second-line treatment for patientswith advanced non-small-cell lung cancer(ZODIAC):A double-blind,randomised,phase 3 trial显示文摘 | Herbst RS Sun Y Eberhardt WE | 2010 | Lancet Oncol2010，11，7： | 1 |
| 14 | Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial 2 intact1显示文摘 | Giaccone G Herbst RS Manegold C | 2004 | J Clin Oncol2004，22，9： | 1 |
| 15 | Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinasc inhibitor ZD1839 in non-small cell lung cancer and other solid tumors显示文摘 | LORUSSO PM HERBST RS RISCHIN D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 16 | Improvements in quality of life and disease-related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors显示文摘 | Lo Russo PM Herbst RS Rischin D | 2003 | Clin Cancer Res2003，9，： | 1 |
| 17 | Vandetanib plus docetaxel versus docetaxel as second line treatment for patients with advanced non-small-cell lung cancer (ZODIAC):a double-blind,randomised,phase 3 trial显示文摘 | Herbst RS Sun Y Eberhardt WE | | 0，，07： | 1 |
| 18 | Efficacy and safety of single- agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer显示文摘 | Herbst RS Davies AM Natale RB | 2007 | Clin Cancer Res2007，13，20： | 1 |
| 19 | Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer a randomized trial显示文摘 | KRIS MG NATALE RB HERBST RS | 2003 | JAMA2003，290，16： | 1 |
| 20 | Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination ( BATTLE ) trial 显示文摘 | Herbst RS Blumenschein GR Kim ES | 2010 | J Clin Oncol2010，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员